NetScientific PLC focused on “execution, execution and execution”

Biomedical and healthcare incubator NetScientific PLC (LON:NSCI) had a busy first half to the year, focusing on “execution, execution, execution”, according to chief executive officer François Martelet.
Backed by its world class scientific advisory boards, the investment company’s emphasis has been on accelerating its core portfolio companies – Wanda, Vortex Biosciences, Glycotest and ProAxsis – towards the commercialisation stage. That will set them up nicely for time when external funding will be needed to capitalise on the market opportunities.
ProAxsis is already on the cusp of fund-raising, and will seek external backers before the end of the year while Wanda, which now has an experienced CEO on board, also plans to seek external funding to capitalise on the significant opportunities in the digital healthcare space.
Martelet said the second half is set to be just as busy for those companies, and as they emerge from the development stage Martelet said the company would be looking to replenish the pipeline.
“We are certainly looking at organic growth … but we are looking at game changing technologies in the UK, in Europe and in the US as well to achieve that goal.”